Antimutagenicity of amifostine against the anticancer drug fotemustine in the Drosophila somatic mutation and recombination (SMART) test

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 679, Issue 1-2, 2009, Pages 1-5

  Aydemir, N ^a   Sevim, N ^a   Celikler, S ^a   Vatan, O ^a   Bilaloglu, R ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Amifostine; Antimutagenicity; Drosophila SMART assay; Fotemustine

Indexed keywords

AMIFOSTINE; FOTEMUSTINE;

ARTICLE; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; FEMALE; GENE MUTATION; GENETIC MARKER; GENETIC RECOMBINATION; GENOTYPE; HETEROZYGOSITY; LARVA; MOLECULAR CLONING; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL;

AMIFOSTINE; ANIMALS; ANTIMUTAGENIC AGENTS; ANTINEOPLASTIC AGENTS; DROSOPHILA MELANOGASTER; MUTAGENICITY TESTS; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RECOMBINATION, GENETIC;

DROSOPHILA MELANOGASTER;

EID: 70249111547     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2009.08.005     Document Type: Article

References (42)

1. ®) cytotoxicity by amifostine in malignant melanoma cell lines. Anti-Cancer Drugs 13 (2002) 141-147
2. Nebel M.C., Larripa I., and Gonzalez-Cid M. Differential antigenotoxic and cytoprotective effect of amifostine in idarubicin-treated mice. Environ. Mol. Mutagen. 39 (2002) 3-9
3. Kurbacher C.M., and Mallmann P.K. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721). Anticancer Res. 18 (1998) 2203-2210
4. Buschini A., Alessandrini C., Martino A., Pasini L., Rizzoli V., Carlo-Stella C., Poli P., and Rossi C. Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells. Biochem. Pharmacol. 63 (2002) 967-975
5. Komaki R., Lee J.S., Milas L., Lee H.K., Fossella F.V., Herbst R.S., Allen P.K., Liao Z.X., Stevens C.W., Lu C., Zinner R.G., Papadimitrakopoulou V.A., Kies M.S., Blumenschein G.R., Pisters K.M., Glisson B.S., Kurie J., Kaplan B., Garza V.P., Mooring D., Tucker S.L., and Cox J.D. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable nonsmall-cell lung cancer: report of a randomized comparative trial. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 1369-1377
6. Majsterek I., Gloc E., Blasiak J., and Reiter R.J. A comparison of the action of amifostine and melatonin on DNA-damaging effects and apoptosis induced by idarubicin in normal and cancer cells. J. Pineal Res. 38 (2005) 254-263
7. Sasse A.D., Clark L.G.D., Sasse E.C., and Clark O.A.C. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 64 (2006) 784-791
8. Andreassen C.N., Gran C., and Lindegaard J.C. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin. Radiat. Oncol. 13 (2003) 62-72
9. Rades D., Fehlauer F., Bajrovic A., Mahlmann B., Rickert E., and Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother. Oncol. 70 (2004) 261-264
10. Vermeulen N.P.E., Commandeur J.N.M., Groot E.J., Wormhoudt L.W., Ramnatshing S., Li Q.J., and Brakenhoff J.P.G. Toxicity of fotemustine in rat hepatocytes and mechanism-based protection against it. Chem. Biol. Interact. 110 (1998) 139-158
11. Winum J.Y., Bouissiere J.L., Passagne I., Evrard A., Montero V., Cuq P., and Montero J.L. Synthesis and biological evaluation of fotemustine analogues on human melanoma cell lines. Eur. J. Med. Chem. 38 (2003) 319-324
12. Kaya B., Creus A., Velazquez A., Yanikoglu A., and Marcos R. Genotoxicity is modulated by ascorbic acid-studies using the wing spot test in Drosophila. Mutat. Res. Genet. Toxicol. Environ. 520 (2002) 93-101
13. Park K.Y., Jung K.O., Rhee S.H., and Choi Y.H. Antimutagenic effects of doenjang (Korean fermented soypaste) and its active compounds. Mutat. Res.: Fundam. Mol. Mech. 523 (2003) 43-53
14. Costa W.F., and Nepomuceno J.C. Protective effects of a mixture of antioxidant vitamins and minerals on the genotoxicity of doxorubicin in somatic cells of Drosophila melanogaster. Environ. Mol. Mutagen. 47 (2006) 18-24
15. St John M.A.R., and Xu T. Insights from model systems. Understanding human cancer in a fly. Am. J. Genet. 61 (1997) 1006-1010
16. Graf U., Abraham S.K., Guzman-Rincon J., and Würgler F.E. Antigenotoxicity studies in Drosophila melanogaster. Mutat. Res. 402 (1998) 203-209
17. In: Lindsley D.L., and Zimm G.G. (Eds). The Genome of Drosophila melanogaster (1992), Academic Press, San Diego 1133
18. Graf U., Würgler F.E., Katz A.J., Frei H., Juon H., Hall C.B., and Kale P.G. Somatic mutation and recombination test in Drosophila melanogaster. Mutat. Res. 271 (1984) 59-67
19. Frei H., Clements J., Howe D., and Würgler F.E. The genotoxicity of anti-cancer drug mitoxantrone in somatic and germ cells. Mutat. Res. 279 (1992) 21-33
20. Frei H., and Würgler F.E. Statistical methods to decide whether mutagenicity test data from Drosophila assays indicate a positive, negative, or inconclusive result. Mutat. Res. 203 (1988) 297-308
21. Frei H., and Würgler F.E. Optimal experimental design and sample size for the statistical evaluation of data from somatic mutation and recombination test (SMART) in Drosophila. Mutat. Res. 334 (1995) 247-258
22. Kastenbaum M.A., and Bowman K.O. Tables for determining the statistical significance of mutation frequencies. Mutat. Res. 9 (1970) 527-549
23. Moraga A.A., and Graf U. Genotoxicity testing of antiparasitic nitrofurans in the Drosophila wing somatic mutation and recombination test. Mutagenesis 4 (1989) 105-110
24. Santos J.H., Graf U., Reguly M.L., and Andrade H.H.R. The synergistic effects of vanillin on recombination predominate over its antimutagenic action in relation to MMC-induced lesions in somatic cells of Drosophila melanogaster. Mutat. Res. 444 (1999) 355-365
25. Sinigaglia M., Lehmann M., Baumgardt P., Amaral V.S., Dihl R.R., Reguly M.L., and Andrade H.H.R. Vanillin as a modulator agent in SMART test: inhibition in the steps that precede N-methyl-Nnitrosourea-, N-ethyl-N-nitrosourea-, ethylmethanesulphonate- and bleomycin-genotoxicity. Mutat. Res. 607 (2006) 225-230
26. Abraham S.K. Antigenotoxicity of coffee in the Drosophila assay for somatic mutation and recombination. Mutagenesis 9 (1994) 383-386
27. Graf U., Moraga A.A., Castro R., and Carrillo E.D. Genotoxicity testing of different types of beverages in the Drosophila wing somatic mutation and recombination test. Food Chem. Toxicol. 32 (1994) 423-430
28. Tripathy N.K., Würgler F.E., and Frei H. Genetic toxicity of six carcinogens and six non-carcinogens in the Drosophila wing spot test. Mutat. Res. 242 (1990) 169-180
29. Karekar V., Joshi S., and Shinde S.L. Antimutagenic profile of three antioxidants in the Ames assay and the Drosophila wing spot test. Mutat. Res. 468 (2000) 183-194
30. Ashby J., Vogel E.W., Tinwell H., Callander R.D., and Shuker D.E.G. Mutagenicity to Salmonella, Drosophila and mouse bone marrow of the human antineoplastic agent fotemustine: prediction of carcinogenic potency. Mutat. Res. 286 (1993) 101-109
31. Celikler S., Bilaloglu R., and Aydemir N. Genotoxic effects induced by fotemustine and vinorelbine in human lymphocytes. Z. Naturforsch. C 61 11-12 (2006) 903-910
32. Brookes P. The early history of the biological alkylating agents. Mutat. Res. 233 (1990) 3-14
33. Moore M.J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmocokinet. 20 (1991) 194-208
34. Mazur L., and Blawat A. Effects of GSH and WR-2721 on induction of micronuclei by cyclophosphamide. Toxicol. Lett. 110 (1999) 67-72
35. 6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 24 (2002) 255-266
36. Santos-Mello R., Deimling L.I., Junior C.L., and De Carvalho T.R. Chemoprotective effect of cysteamine against the induction of micronuclei by methyl methanesulfonate and cyclophosphamide. Genet. Mol. Biol. 28 (2005) 156-160
37. Grochova D., and Smardova J. The antimutagenic and cytoprotective effects of amifostine: the role of p53. J. Appl. Biomed. 5 (2007) 171-178
38. Grdina D.J., Nagy B., Hill C.K., Wells R.L., and Peraino C. The radioprotector WR1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells. Carcinogenesis 6 (1985) 929-931
39. Grdina D.J., Kataoka Y., Basic I., and Perrin J. The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation. Carcinogenesis 13 (1992) 811-814
40. Kataoka Y., Perrin J., Hunter N., Milas L., and Grdina D.J. Antimutagenic effects of amifostine: clinical implications. Semin. Oncol. 23 (1996) 53-57
41. Fuentes J.L., Alonso A., Cuetara E., Vernhe M., Alvarez N., Sanchez-Lamar A., and Llagostera M. Usefulness of the SOS Chromotest in the study of medicinal plants as radioprotectors. Int. J. Radiat. Biol. 82 (2006) 323-329
42. De Souza C.A., Santini G., Marino G., Nati S., Congiu A.M., Vigorito A.C., and Damasio E. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study. Braz. J. Med. Biol. Res. 33 (2000) 791-798